News
CNTG
0.4799
+4.10%
0.0189
Weekly Report: what happened at CNTG last week (0415-0419)?
Weekly Report · 3d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Redwoods Acquisition stock is rocketing more than 84% on details of a shareholder meeting. The biggest pre-market stock movers this morning are shareholder meetings, earnings reports, a dividend and more. Tritium DCFC stock is crashing over 61% after warning of insolvency.
Investorplace · 6d ago
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. Rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results. Redwoods Acquisition Corp. Shares gained 141% to $17.83 in pre- market trading. Netflix Inc. Shares jumped around 32% on Thursday after reporting upbeat results for its first quarter.
Benzinga · 04/19 09:45
Weekly Report: what happened at CNTG last week (0408-0412)?
Weekly Report · 04/15 11:27
Weekly Report: what happened at CNTG last week (0401-0405)?
Weekly Report · 04/08 11:31
Centogene N.V. Faces Nasdaq Compliance Challenge
TipRanks · 04/02 20:58
Centogence receives Nasdaq non-compliance letter
Healthcare Centogence receives Nasdaq non-compliance letter. Centogene N.V. (CNTG) Stock is not in compliance with minimum bid price requirement. The company intends to actively monitor the bid price for its common shares and will evaluate all options to resolve the deficiency.
Seeking Alpha · 04/02 20:36
Centogene Receives Non-Compliance Notification Letter Dated March 27, 2024, From Nasdaq
Benzinga · 04/02 20:32
CENTOGENE RECEIVES NASDAQ NON-COMPLIANCE NOTICE
Reuters · 04/02 20:30
Weekly Report: what happened at CNTG last week (0325-0329)?
Weekly Report · 04/01 11:29
Weekly Report: what happened at CNTG last week (0318-0322)?
Weekly Report · 03/25 11:32
Centogene, Takeda extend diagnostic partnership
Healthcare Centogene, Takeda extend diagnostic partnership. German biotech will continue to provide its testing solutions to the Japanese pharma giant. The two companies will work together to diagnose patients with inherited metabolic diseases. CNTG and TAK first established a partnership in 2015.
Seeking Alpha · 03/19 11:41
CENTOGENE and Takeda Boost Genetic Testing for LSDs
TipRanks · 03/19 11:28
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
Centogene extends partnership with Takeda to diagnose patients with Lysosomal Storage Disorders. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome. CENTOGENE will continue to provide access to testing for patients around the world.
Benzinga · 03/19 10:32
Weekly Report: what happened at CNTG last week (0311-0315)?
Weekly Report · 03/18 11:30
Weekly Report: what happened at CNTG last week (0304-0308)?
Weekly Report · 03/11 11:26
Weekly Report: what happened at CNTG last week (0226-0301)?
Weekly Report · 03/04 11:29
Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge
Healthcare Centogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plunge Feb. 28. CNTG -18.75% premarket to $0.77. Centogene (CNTG) received a staff determination letter from Nasdaq on Feb. 27 to delist the company's securities.
Seeking Alpha · 02/28 12:18
Centogene Says It Is Exploring A Range Of Strategic Alternatives Focused On Sustainable Long-term Value Creation For The Benefit Of Its Stakeholders
The company received a staff determination letter on Feb. 27, 2024. Nasdaq delisted the company's securities from The Nasdaq Global Market due to non-compliance with the minimum $15 million market value requirement. The company's stock is listed on the Nasdaq Stock Market.
Benzinga · 02/28 11:33
CENTOGENE Explores Strategic Alternatives
Centogene is the essential life science partner for data-driven answers in rare and neurodegenerative diseases. The Company has decided to explore a range of strategic alternatives for the benefit of its stakeholders. Centogene is a company of Centogene N.V. In Germany.
Barchart · 02/28 05:30
More
Webull provides a variety of real-time CNTG stock news. You can receive the latest news about Centogene N.V. through multiple platforms. This information may help you make smarter investment decisions.
About CNTG
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.